Cutaneous Lupus: Identification, Systemic Screening, and What’s on the Horizon

In this episode of Topical Conversations, Joseph Merola, MD, and Scott Elman, MD, examine the evolving understanding of cutaneous lupus erythematosus (CLE) and its place within the broader spectrum of connective tissue disease. Their discussion highlights the dermatologist’s central role, not only in recognizing and treating skin manifestations, but also in screening for systemic involvement and coordinating care when needed.  

A disease state in transition

Advances in understanding the pathophysiology of cutaneous lupus are beginning to translate into therapeutic momentum. What was once a space with limited targeted options is now seeing the emergence of multiple investigational therapies, reflecting a shift toward more mechanism-driven treatment approaches.  

Clinical identification: recognizing key subtypes

Cutaneous lupus is often categorized into several major subtypes, each with distinct clinical features:

• Acute cutaneous lupus: Classically presents with a malar rash that spares the nasolabial folds  
• Subacute cutaneous lupus: Typically papulosquamous or annular, often in sun-exposed areas such as the shoulders and arms; may be drug-induced  
• Chronic cutaneous lupus: The largest category, with discoid lupus as the most familiar subtype; characterized by scarring plaques that can lead to permanent hair loss and disfigurement  

Recognizing these patterns remains foundational to diagnosis and helps guide both evaluation and management.  

Screening for systemic disease: a core responsibility

A key theme emphasized in this discussion is the importance of routinely assessing for systemic lupus erythematosus (SLE) in patients with cutaneous disease.

Practical screening approaches may include:

• Laboratory evaluation: ANA testing as an initial screen, along with CBC, CMP, and urinalysis  
• Clinical review of systems: Assessing for joint pain, mucosal involvement, and other systemic symptoms  
• Ongoing surveillance: Repeating assessments every 3 to 6 months, rather than relying on a single evaluation  

Importantly, a negative initial workup does not exclude future systemic involvement. Dermatologists play a critical role in maintaining longitudinal awareness and determining when to involve rheumatology colleagues.  

Patient burden: beyond skin findings

The impact of cutaneous lupus extends well beyond visible disease. Quality-of-life studies suggest that the burden experienced by patients may be comparable to chronic conditions such as hypertension, type 2 diabetes, congestive heart failure, and recent myocardial infarction.

This burden reflects both active symptoms and long-term consequences, including scarring and disfigurement  

Early recognition and appropriate treatment are essential to mitigate these outcomes.  

Emerging therapies: expanding possibilities

After decades of limited progress, the treatment landscape for lupus is beginning to broaden, with several agents under investigation for cutaneous and systemic disease:

• Anifrolumab: Approved for SLE, with ongoing phase 3 evaluation in CLE
• Litifilimab: Targets plasmacytoid dendritic cells, with downstream effects on type I interferon and other cytokines  
• Deucravacitinib: Approved for psoriasis, currently under investigation in lupus with early signals in CLE  
• Enpatoran: Early data suggest potential activity in CLE  

These developments reflect a growing focus on targeted immunologic pathways relevant to both skin and systemic manifestations.  

Comanagement: aligning dermatology and rheumatology

For patients with overlapping cutaneous and systemic disease, coordination of care is essential. Thoughtful selection of therapies may allow for alignment across organ systems, with the goal of controlling disease activity while minimizing progression and long-term damage.

Dermatologists play a key role in initiating and optimizing treatment for skin disease, monitoring for systemic involvement, and collaborating with rheumatology when indicated  

As familiarity with these therapies grows, opportunities to refine treatment strategies across specialties are likely to expand.  

Key takeaways

• Cutaneous lupus encompasses multiple clinical subtypes, each with distinct presentation and implications for management  
• Dermatologists are central to both diagnosis and ongoing screening for systemic lupus involvement  
• Systemic evaluation should include labs, review of systems, and periodic reassessment over time  
• The burden of disease extends beyond visible lesions, with significant quality-of-life impact and risk of permanent damage  
• A growing pipeline of targeted therapies is beginning to reshape treatment considerations in both CLE and SLE  
• Comanagement with rheumatology is critical for patients with systemic involvement